Deepening losses in FY2025 reflect aggressive clinical advancement and organizational scaling, offset by successful Phase 3 DRAGON trial results and a fortified balance sheet following substantial capital raises.
Key takeaways
Operating loss widened 110% to $84.2M on Phase 3 trial execution and scaling costs
Ongoing Phase 3 PHOENIX trial in Geographic Atrophy fully enrolled with 530 subjects